Item 2.02. Results of Operations and Financial Condition.



As required by the PRC Securities Laws, the Prospectus contains historical
financial information of the Company that was prepared in accordance with the
China Accounting Standards for Business Enterprises - Basic Standard ("CAS") and
other applicable PRC accounting rules, guidance and interpretations, including
but not limited to the China Securities Regulatory Commission's Compilation Rule
for Information Disclosure by Companies Offering Securities to the Public No. 15
- General Rules for Financial Statement (2014 revised), and Compilation Rule for
Information Disclosure by Companies Offering Securities to the Public No. 24 -
Special Provisions on Information Disclosure in Financial Statements of Pilot
Innovative Red-chip Companies on the Sci-Tech Innovation Board (together with
CAS, "PRC GAAP") for the years ended December 31, 2018, 2019 and 2020 and the
six months ended June 30, 2021, certain historical financial results for the
nine months ended September 30, 2021. PRC GAAP are different from the accounting
principles generally accepted in the United States ("U.S. GAAP"). The key
differences between such financial information prepared in accordance with PRC
GAAP and those prepared in accordance with U.S. GAAP, which was previously filed
with the U.S. Securities and Exchange Commission (the "SEC"), were summarized in
the Company's Current Report on Form 8-K filed with the SEC on June 30, 2021.

As required by the PRC Securities Laws, the Prospectus contains the Company's
research and development expenses allocated by key products and other research
and development projects ("R&D Expenses") for the years ended December 31, 2018,
2019 and 2020, and the six months ended June 30, 2021 ("Reporting Period")
prepared in accordance with PRC GAAP. The R&D Expenses for the Reporting Period
prepared in accordance with U.S. GAAP are attached hereto as Exhibit 99.1 to
this Current Report on Form 8-K and incorporated herein by reference.

As required by the PRC Securities Laws, the Prospectus contains an estimated
forecast of the preliminary range of certain financial results expected for the
year ending December 31, 2021, which mainly include the expected total revenue
and the net loss attributable to the Company (the "Estimated Range of Financial
Results"). The Estimated Range of Financial Results is prepared in accordance
with the PRC GAAP and presented in RMB. The Company's independent registered
public accountants have not audited, reviewed or performed any procedures with
respect to the Estimated Range of Financial Results and accordingly do not
express an opinion or any other form of assurance with respect thereto. The
Estimated Range of Financial Results could change as a result of further review
and the actual results for the year ending December 31, 2021 could differ from
the Estimated Range of Financial Results as a result of changes in underlying
circumstances or events that cause management's assumptions and estimates to
differ from current expectations. The corresponding Estimated Range of Financial
Results prepared in accordance with the accounting principles generally accepted
in the United States are attached hereto as Exhibit 99.1 to this Current Report
on Form 8-K and incorporated herein by reference.





--------------------------------------------------------------------------------

The Prospectus is publicly available in Chinese language only on the website
maintained by the Shanghai Stock Exchange at www.sse.com.cn. The Prospectus and
the information contained on the Shanghai Stock Exchange's website are not part
of this Current Report on Form 8-K and shall not be deemed filed or furnished by
the Company with the SEC, nor shall they be deemed incorporated by reference in
any filing by the Company under the Securities Act of 1933, as amended (the
"Securities Act"), or the Securities Exchange Act of 1934, as amended (the
"Exchange Act").

The information in Item 2.02 of this Current Report on Form 8-K and in Exhibit
99.1 is intended to be furnished and shall not be deemed "filed" for purposes of
Section 18 of the Exchange Act, or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act or the Exchange Act, except as expressly set forth by
specific reference in such filing.

Item 8.01. Other Events.

On November 16, 2021, the Company's application for the registration of the Proposed Issue of RMB Shares was granted by the CSRC. The consummation of the STAR Offering is subject to, among other things, market conditions.



On November 14, 2021, BeiGene and NewBridge Pharmaceuticals, a specialty company
in the Middle East and North Africa (MENA) regions established to bridge the
access gap by partnering with global pharma and biotech companies, announced
that BRUKINSA® (zanubrutinib) has received approval from the Saudi Food and Drug
Authority (SFDA) for the treatment of adult patients with mantle cell lymphoma
(MCL) who have received at least one prior therapy. BeiGene and NewBridge
Pharmaceuticals are working together to bring BRUKINSA to healthcare providers
and people living with MCL in Saudi Arabia and other MENA markets following
regulatory approvals. The full text of this press release is filed as Exhibit
99.2 to this Current Report on Form 8-K and is incorporated herein by reference.



--------------------------------------------------------------------------------

Forward-Looking Statements



This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and other
securities laws, including statements regarding the Proposed Issue of RMB Shares
under the general mandate to be listed on the STAR Market and the Estimated
Range of Financial Results. Actual results may differ materially from those
indicated in the forward-looking statements as a result of various important
factors, including the possibility that the conditions, including market
conditions, will not be met and that BeiGene will be unable to consummate the
Proposed Issue of RMB Shares; the possibility that BeiGene will not realize the
expected benefits of the transaction; the possibility that the final financial
results will be different from the preliminary Estimated Range of Financial
Results; BeiGene's ability to demonstrate the efficacy and safety of its drug
candidates; the clinical results for its drug candidates, which may not support
further development or marketing approval; actions of regulatory agencies, which
may affect the initiation, timing and progress of clinical trials and marketing
approval; BeiGene's ability to achieve commercial success for its marketed
medicines and drug candidates, if approved; BeiGene's ability to obtain and
maintain protection of intellectual property for its medicines and technology;
BeiGene's reliance on third parties to conduct drug development, manufacturing
and other services; BeiGene's limited experience in obtaining regulatory
approvals and commercializing pharmaceutical products and its ability to obtain
additional funding for operations and to complete the development and
commercialization of its drug candidates and achieve and maintain profitability;
the impact of the COVID-19 pandemic on the BeiGene's clinical development,
regulatory, commercial, and other operations, as well as those risks more fully
discussed in the section entitled "Risk Factors" in BeiGene's most recent
quarterly report on Form 10-Q as well as discussions of potential risks,
uncertainties, and other important factors in BeiGene's subsequent filings with
the U.S. Securities and Exchange Commission. All information in this Current
Report is as of the date of this Current Report, and BeiGene undertakes no duty
to update such information unless required by law.

The Proposed Issue of RMB Shares under the general mandate is subject to, among
other things, market conditions, and thus may or may not proceed. Shareholders
and potential investors of the Company should be aware that there is no
assurance that the Proposed Issue of RMB Shares will materialize or as to when
it may materialize. Shareholders and potential investors of the Company should
exercise caution when dealing in the securities of the Company.

Further announcement(s) or filings will be made by the Company in accordance
with the applicable laws and regulations on any material updates and progress in
connection with the Proposed Issue of RMB Shares as and when appropriate. This
Current Report is for information purposes only and does not constitute any
invitation or offer to acquire, purchase or subscribe for the securities of the
Company.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Financial Information, furnished herewith

       99.2               Press Release titled "BeiGene and NewBridge

Pharmaceuticals Announce Approval


                          in Saudi Arabia of BRUKINSA® (Zanubrutinib) for

the Treatment of Patients


                          with Relapsed or Refractory Mantle Cell

Lymphoma", issued by BeiGene, Ltd. on

November 14, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses